anti-PD1 monotherapy

Anti-PD1 monotherapy refers to the therapeutic use of a single-agent monoclonal antibody that targets the Programmed Cell Death Protein 1 (PD-1) receptor. PD-1 is a key immune checkpoint protein expressed on the surface of T cells; when it binds to its ligands, PD-L1 or PD-L2, it transmits an inhibitory signal that reduces T-cell activation and proliferation. By blocking this interaction, anti-PD1 antibodies effectively 'release the brakes' on the immune system, enhancing the ability of T cells to recognize and eliminate cancer cells. This treatment modality is a cornerstone of modern oncology and is utilized across a broad spectrum of malignancies, including melanoma, non-small cell lung cancer, and renal cell carcinoma. Recent clinical reports also highlight its efficacy in specific subsets of pediatric brain tumors, such as replication repair deficient (RRD) medulloblastoma.

Other names

anti-PD1 monotherapyanti-PD-1 monotherapyanti-PD 1 monotherapyPD-1 inhibitor monotherapyPD1 inhibitor monotherapyPD 1 inhibitor monotherapy